Cryoport, Inc. (NASDAQ:CYRX) Receives $11.50 Average PT from Brokerages

Shares of Cryoport, Inc. (NASDAQ:CYRXGet Free Report) have earned an average recommendation of “Moderate Buy” from the six analysts that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $11.50.

CYRX has been the subject of a number of analyst reports. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Cryoport in a research note on Wednesday, March 5th. Guggenheim initiated coverage on shares of Cryoport in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company.

Check Out Our Latest Report on Cryoport

Hedge Funds Weigh In On Cryoport

A number of institutional investors and hedge funds have recently bought and sold shares of CYRX. Quest Partners LLC grew its position in Cryoport by 168.5% in the 3rd quarter. Quest Partners LLC now owns 29,083 shares of the company’s stock valued at $236,000 after buying an additional 18,252 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in Cryoport in the third quarter worth about $326,000. Intech Investment Management LLC bought a new stake in Cryoport in the third quarter worth about $105,000. Charles Schwab Investment Management Inc. raised its position in Cryoport by 0.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after acquiring an additional 2,226 shares in the last quarter. Finally, Algert Global LLC raised its position in Cryoport by 282.7% in the third quarter. Algert Global LLC now owns 247,483 shares of the company’s stock worth $2,007,000 after acquiring an additional 182,808 shares in the last quarter. Institutional investors own 92.90% of the company’s stock.

Cryoport Stock Performance

CYRX stock opened at $6.41 on Thursday. Cryoport has a 1 year low of $4.58 and a 1 year high of $20.11. The stock has a market capitalization of $319.92 million, a price-to-earnings ratio of -1.90 and a beta of 1.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The stock’s fifty day moving average is $7.07 and its two-hundred day moving average is $7.48.

Cryoport (NASDAQ:CYRXGet Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). The firm had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. During the same quarter in the prior year, the business earned ($0.29) earnings per share. On average, research analysts predict that Cryoport will post -0.99 EPS for the current year.

About Cryoport

(Get Free Report

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

Featured Stories

Analyst Recommendations for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.